Equillium, Inc. (EQ) Research

Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.

Market snapshot

Symbol
EQ
Price
$3.05
Day change
+2.01%
Market cap
$108.3M
P/E ratio
-15.41x
52-week range
0.27-3.45
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$6.25

Peer companies

  • Coeptis Therapeutics, Inc. (COEP)
  • Cue Biopharma, Inc. (CUE)
  • Fortress Biotech, Inc. (FBIO)
  • Century Therapeutics, Inc. (IPSC)
  • Medicus Pharma Ltd. Common Stock (MDCX)
  • NRx Pharmaceuticals, Inc. (NRXP)
  • OS Therapies Incorporated (OSTX)
  • Outlook Therapeutics, Inc. (OTLK)

Recent insider activity

  • Zedelmayer Christine — M-Exempt (14584 shares) on 2026-06-05
  • Zedelmayer Christine — S-Sale (14584 shares) on 2026-06-05
  • Zedelmayer Christine — M-Exempt (14584 shares) on 2026-06-05
  • Connelly Stephen — S-Sale (200000 shares) on 2026-06-04
  • Connelly Stephen — S-Sale (30975 shares) on 2026-06-05

Open Equillium, Inc. (EQ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.